
Episode 24: A Between the Biotech Waves conversation with John Hoffman, managing director & head of healthcare equity capital markets at Credit Suisse
Between the Biotech Waves
The Path to Financing in 2023
Do you have a sense of companies that may have gone at last year that were actually unable to finance and you know is do you think that people in 23 may be more receptive to those companies again. Yeah I think we've seen something very similar to the private market right and where people you know companies went out for a second quarter in 2022 to raise but they weren't successful. And then on the situation there's always a platform technology that is so exciting and so disruptive and is well credentialed with a managed team and existing investors that provide a foundational base that those opportunities can still get funded in the public markets. The IPO market currently is not is not really conditioned for that type of opportunity.